# Study Evaluating rFIX; BeneFIX in Severe Hemophilia B

> **NCT00037557** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 20 (—)

## Conditions studied

- Hemophilia B

## Interventions

- **DRUG:** BeneFIX

## Key facts

- **NCT ID:** NCT00037557
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 20 (—)
- **Last updated:** 2007-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00037557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00037557, "Study Evaluating rFIX; BeneFIX in Severe Hemophilia B". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00037557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*